Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:51 2024-04-24 am EDT			5-day change	1st Jan Change
222.2 ^CHF	-3.27%		+0.95%	-9.12%

Apr. 24	ROCHE HOLDINGS AG : DZ Bank reiterates its Buy rating	ZD
Apr. 24	Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red	MT

ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating

March 11, 2022 at 02:54 am EST

Analyst Richard Vosser from JP Morgan research gives the stock a Neutral rating. Previously set at CHF 390, the target price is lowered to CHF 370.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : DZ Bank reiterates its Buy rating	Apr. 24	ZD
Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red	Apr. 24	MT
ROCHE HOLDING : In line quarterly results won’t cut it for Roche	Apr. 24
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	Apr. 24
Transcript : Roche Holding AG, Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	Apr. 24
ROCHE HOLDINGS AG : Barclays remains Neutral	Apr. 24	ZD
ROCHE HOLDINGS AG : UBS reaffirms its Neutral rating	Apr. 24	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Roche Eyes Potential M&A Deals Amid Pipeline Restructure	Apr. 24	MT
Shares jump on tech boost; fragile yen on intervention watch	Apr. 24	RE
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	Apr. 24	ZD
Roche Sees Return to Growth Ahead After Forex, Post-pandemic Slump Hit First-quarter Sales	Apr. 24	MT
ROCHE HOLDINGS AG : Jefferies reaffirms its Neutral rating	Apr. 24	ZD
Roche: 2% growth in sales at constant exchange rates in Q1	Apr. 24	CF
ROCHE HOLDINGS AG : Buy rating from Bernstein	Apr. 24	ZD
European shares flat, with focus on mixed bag of earnings	Apr. 24	RE
Correction to Roche Article	Apr. 24	DJ
Roche Sales Decline on Currency Hit	Apr. 24	DJ
Swiss Drugmaker Roche's Q1 Sales Fall; FY24 Outlook Confirmed	Apr. 24	MT
Roche Q1 sales down 6% on forex effect, loss of COVID revenue	Apr. 24	RE
Roche Holding AG Reports Sales Results for the First Quarter Ended March 2024	Apr. 24	CI
Roche Holding AG Provides Earnings Guidance for the Year 2024	Apr. 24	CI
EMEA Morning Briefing: Shares May Rise as Investors Brace for Earnings	Apr. 24	DJ
Swiss Equities Flash Green; Middle East Tensions Rise	Apr. 19	MT
Roche: approval in lung cancer in the United States	Apr. 19	CF

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

2024-05-14 - BofA Securities Health Care Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

222.2 CHF

Average target price

281.1 CHF

Spread / Average Target

+26.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-9.12%	204B
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B
AMGEN INC.	-5.21%	147B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals